Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering

Anteris Technologies Global Corp. (“Anteris” or the “Company”) has announced the pricing of its public offering of common stock, marking a major step in the company’s efforts to strengthen its financial position and accelerate its clinical and commercial initiatives. The announcement was made on January 20, 2026, and reflects investor support for Anteris’s strategic goals in the structural heart disease space.

Overview of the Public Offering

Anteris has priced an underwritten public offering of 34,782,609 shares of its common stock at a public offering price of $5.75 per share. Prior to deducting underwriting discounts, commissions, and estimated offering expenses, the company expects to receive approximately $200 million in gross proceeds from the offering.

All of the shares in the public offering are being sold by the company itself, as opposed to existing shareholders selling their holdings. This indicates that the funds raised will flow directly into Anteris’s operations, supporting research, development, and growth.

The offering is expected to close on or around January 22, 2026, subject to customary closing conditions.

Underwriter Option to Purchase Additional Shares

Anteris has granted the underwriters a 30-day option to purchase up to an additional 5,217,391 shares of common stock at the public offering price, less underwriting discounts and commissions. This option is commonly known as an “overallotment” or “greenshoe option” and is used to help stabilize the stock price after the offering closes.

Strategic Private Placement with Medtronic

In connection with the offering, Anteris has entered into a stock purchase agreement with Medtronic plc (through a wholly owned subsidiary) dated January 20, 2026. Under the terms of this agreement, Anteris may sell up to $90 million worth of shares of its common stock to Medtronic in a private placement that is exempt from the registration requirements of the U.S. Securities Act of 1933.

The price per share in the private placement will be the same as the public offering price. Medtronic’s minimum purchase will equal 16 % of the number of shares outstanding after the offering, and its maximum purchase will equal 19.99 % of the number of shares outstanding after the offering.

Importantly, completion of the private placement is contingent upon completion of the public offering. However, the public offering itself is not dependent on the private placement closing.

Purpose of the Offering and Use of Proceeds

Anteris intends to use the net proceeds from the offering, together with its existing cash and cash equivalents and net proceeds from the Medtronic private placement, to support a range of strategic priorities aimed at accelerating the company’s growth and clinical development efforts.

Funding Clinical Development

One of the key uses of the funds is to support the ongoing DurAVR® Transcatheter Heart Valve (“DurAVR® THV”) global pivotal trial, known as the PARADIGM Trial. This study is focused on patients with severe aortic stenosis and represents a critical step in advancing one of Anteris’s lead medical technologies toward broader approval and commercialization.

The DurAVR® THV is designed to mimic the function of a healthy human aortic valve and uses proprietary ADAPT® tissue technology, which has been clinically used for over a decade and distributed in tens of thousands of patients worldwide. This innovative approach aims to enhance durability and performance for patients undergoing transcatheter aortic valve replacement (TAVR) procedures.

Manufacturing Expansion

A portion of the proceeds will also be allocated to expanding manufacturing capabilities to ensure that Anteris can scale production as demand grows, particularly if the company achieves regulatory milestones or commercial traction in key markets.

Research and Development Initiatives

Anteris plans to fund ongoing research and development activities in collaboration with its subsidiary, v2vmedtech, Inc., focusing on next-generation cardiac devices and technologies that may further differentiate the company’s portfolio in the structural heart space.

Working Capital and Corporate Purposes

Beyond clinical and manufacturing investment, the remaining funds are expected to be used for general working capital and other corporate purposes, giving Anteris the financial flexibility to execute its strategic roadmap.

Underwriters and Advisors

Anteris has engaged leading financial institutions to manage the offering. Barclays, Wells Fargo Securities, and Cantor Fitzgerald are serving as joint book-running managers for the public offering. Additionally, Barrenjoey Markets Pty Limited is acting as a financial advisor for investors in the Asia-Pacific and select international jurisdictions.

is also acting as the sole placement agent for the private placement with Medtronic. These firms bring significant expertise in structuring and executing equity offerings on a global scale.

Regulatory and Legal Framework

The shares in the public offering are being offered under a registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective on January 8, 2026. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website.

Because the shares offered in the private placement have not been registered under the Securities Act, they may not be offered or sold in the United States except under specific exemptions or after effective registration. This is a standard condition for private placement transactions.

About Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a dual-listed company on NASDAQ and the Australian Securities Exchange (ASX), trading under the ticker symbol AVR. The company is focused on designing, developing, and commercializing structural heart solutions that aim to improve the lives of patients with cardiovascular disease.

Founded in Australia with operational presence in the United States and other global markets, Anteris leverages multidisciplinary expertise to innovate next-generation heart valve technologies. The company’s flagship product, the DurAVR® THV, employs proprietary biomimetic design and advanced tissue processing to enhance performance and patient outcomes in TAVR procedures.

Forward-Looking Statements and Risks

The press release contains forward-looking statements, which are statements that describe Anteris’s future intentions, plans, expectations, and beliefs. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed. Examples include statements regarding the timing of the offering’s closing, the use of proceeds, and anticipated growth opportunities.

Investors are cautioned not to place undue reliance on these forward-looking statements, which are subject to risks described in Anteris’s SEC filings and other disclosures. Except as required by law, Anteris does not undertake any obligation to update these statements to reflect future events or developments.

Significance of the Offering

This $200 million public offering, together with the potential $90 million Medtronic private placement, represents a substantial capital raise for Anteris. It provides the company with enhanced financial resources to drive its clinical programs, expand manufacturing, bolster R&D initiatives, and support broader corporate operations.

Such a funding event also indicates strong investor confidence in Anteris’s business model and technology pipeline, particularly as it advances towards key clinical milestones. The ability to secure strategic investment from a major medical technology company like Medtronic further underscores the potential value of Anteris’s products and long-term vision in the structural heart market.

#AnterisTechnologies #PublicOffering #MedtronicInvestment #DurAVRTrial #SlimScan #GrowthStocks #CANSLIM